Diplazium esculentum (Retz.) Sw. reduces BACE-1 activities and amyloid peptides accumulation in Drosophila models of Alzheimer's disease.
Alzheimer Disease
/ drug therapy
Amyloid Precursor Protein Secretases
/ metabolism
Amyloid beta-Peptides
/ metabolism
Animals
Antioxidants
/ chemistry
Behavior, Animal
Biological Products
Biomarkers
Disease Models, Animal
Drosophila
Ferns
/ chemistry
Gene Expression
Humans
Peptide Fragments
/ metabolism
Phytochemicals
/ chemistry
Plant Extracts
/ chemistry
Protein Aggregates
/ drug effects
Protein Aggregation, Pathological
/ drug therapy
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
10 12 2021
10 12 2021
Historique:
received:
01
08
2021
accepted:
26
11
2021
entrez:
11
12
2021
pubmed:
12
12
2021
medline:
27
1
2022
Statut:
epublish
Résumé
Alzheimer's disease (AD), one type of dementia, is a complex disease affecting people globally with limited drug treatment. Thus, natural products are currently of interest as promising candidates because of their cost-effectiveness and multi-target abilities. Diplazium esculentum (Retz.) Sw., an edible fern, inhibited acetylcholinesterase in vitro, inferring that it might be a promising candidate for AD treatment by supporting cholinergic neurons. However, evidence demonstrating anti-AD properties of this edible plant via inhibiting of neurotoxic peptides production, amyloid beta (Aβ), both in vitro and in vivo is lacking. Thus, the anti-AD properties of D. esculentum extract both in vitro and in Drosophila models of Aβ-mediated toxicity were elucidated. Findings showed that an ethanolic extract exhibited high phenolics and flavonoids, contributing to antioxidant and inhibitory activities against AD-related enzymes. Notably, the extract acted as a BACE-1 blocker and reduced amyloid beta 42 (Aβ42) peptides in Drosophila models, resulting in improved locomotor behaviors. Information gained from this study suggested that D. esculentum showed potential for AD amelioration and prevention. Further investigations in vertebrates or humans are required to determine the effective doses of D. esculentum against AD, particularly via amyloidogenic pathway.
Identifiants
pubmed: 34893659
doi: 10.1038/s41598-021-03142-w
pii: 10.1038/s41598-021-03142-w
pmc: PMC8664832
doi:
Substances chimiques
Amyloid beta-Peptides
0
Antioxidants
0
Biological Products
0
Biomarkers
0
Peptide Fragments
0
Phytochemicals
0
Plant Extracts
0
Protein Aggregates
0
amyloid beta-protein (1-42)
0
Amyloid Precursor Protein Secretases
EC 3.4.-
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
23796Informations de copyright
© 2021. The Author(s).
Références
J Evid Based Complementary Altern Med. 2016 Oct;21(4):NP11-7
pubmed: 26438716
Med Chem. 2016;12(3):226-37
pubmed: 26527156
PLoS One. 2012;7(7):e40569
pubmed: 22808195
Medicines (Basel). 2018 Aug 25;5(3):
pubmed: 30149600
Exp Cell Res. 2018 Jan 15;362(2):461-471
pubmed: 29247619
P T. 2010 Apr;35(4):208-11
pubmed: 20498822
Med Res Rev. 2020 Jan;40(1):339-384
pubmed: 31347728
J Basic Clin Physiol Pharmacol. 2015 Jul;26(4):395-401
pubmed: 25719308
Molecules. 2018 Dec 08;23(12):
pubmed: 30544832
Brain Struct Funct. 2010 Mar;214(2-3):245-62
pubmed: 19967412
Annu Rev Neurosci. 2011;34:185-204
pubmed: 21456963
Lancet Neurol. 2019 Jan;18(1):88-106
pubmed: 30497964
Molecules. 2014 Nov 19;19(11):19180-208
pubmed: 25415479
Molecules. 2020 Aug 14;25(16):
pubmed: 32824050
Anal Biochem. 1996 Jul 15;239(1):70-6
pubmed: 8660627
Biol Pharm Bull. 2009 Aug;32(8):1433-8
pubmed: 19652386
Cold Spring Harb Perspect Med. 2011 Sep;1(1):a006189
pubmed: 22229116
Cold Spring Harb Perspect Biol. 2009 Dec;1(6):a000232
pubmed: 20457557
Drug Des Devel Ther. 2019 Oct 18;13:3591-3605
pubmed: 31695329
ScientificWorldJournal. 2013 Dec 29;2013:162750
pubmed: 24470791
Prev Nutr Food Sci. 2019 Sep;24(3):327-337
pubmed: 31608259
J Alzheimers Dis. 2013;37(2):343-55
pubmed: 23948888
Am J Chin Med. 2016;44(7):1325-1347
pubmed: 27776428
Molecules. 2020 Jun 03;25(11):
pubmed: 32503261
Nat Protoc. 2007;2(4):875-7
pubmed: 17446889
Antioxid Redox Signal. 2013 Sep 10;19(8):823-35
pubmed: 23249141
PLoS One. 2011;6(6):e20799
pubmed: 21673973
J Agric Food Chem. 2000 Aug;48(8):3597-604
pubmed: 10956156
Biochem Pharmacol. 2003 Feb 1;65(3):407-16
pubmed: 12527333
Oncotarget. 2016 Oct 18;7(42):67716-67731
pubmed: 27626494
Acta Pharmacol Sin. 2009 Jan;30(1):25-30
pubmed: 19060918
Biol Open. 2016 Aug 15;5(8):1030-9
pubmed: 27387531
J Agric Food Chem. 2003 May 21;51(11):3273-9
pubmed: 12744654
Curr Neuropharmacol. 2016;14(1):101-15
pubmed: 26813123
PLoS Biol. 2010 Mar 16;8(3):e1000334
pubmed: 20305716
J Neurochem. 2003 Oct;87(1):172-81
pubmed: 12969264
Science. 2006 Nov 3;314(5800):777-81
pubmed: 17082447
Heliyon. 2019 Nov 19;5(11):e02768
pubmed: 31768435
Proc Natl Acad Sci U S A. 1996 Nov 12;93(23):13170-5
pubmed: 8917563
J Neurol Sci. 1982 Dec;57(2-3):407-17
pubmed: 7161627
Trends Biochem Sci. 2005 Jul;30(7):413-22
pubmed: 15949939
Cell Metab. 2011 Feb 2;13(2):139-48
pubmed: 21284981
Genesis. 2002 Sep-Oct;34(1-2):1-15
pubmed: 12324939
Biochim Biophys Acta. 2008 May;1780(5):819-25
pubmed: 18295609
Nature. 1991 Jul 18;352(6332):239-41
pubmed: 1906990
Neurobiol Dis. 2009 Feb;33(2):274-81
pubmed: 19049874
Curr Drug Targets. 2017;18(13):1487-1498
pubmed: 27809746
Foods. 2020 Sep 02;9(9):
pubmed: 32887386
Mol Cell Biochem. 2020 Jan;463(1-2):161-173
pubmed: 31595422
BMC Complement Altern Med. 2014 Mar 05;14:88
pubmed: 24597901